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Monoclonal antibodies restricted to Mycobacterium tuberculosis can measure epitope-
specific antibody levels in a competition assay. Immunodominant epitopes were defined
from clinical samples and related to the clinical spectrum of disease. Antibody to
the immunodominant epitopes was associated with HLA-DR15. Occupational exposure
showed a different response and was consistent with recognition of dormancy-related
proteins and protection despite exposure to tuberculosis (TB). Studies in leprosy revealed
the importance of immune deviation and the relationships between T and B cell epitopes.
During treatment, antibody levels increased, epitope spreading occurred, but the affinity
constants remained the same after further antigen exposure, suggesting constraints on
the process of epitope selection. Epitope-specific antibody levels have a potential role as
biomarkers for new vaccines which might prevent the progression of latent to active TB
and as tools to measure treatment effects on subpopulations of tubercle bacilli.
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INTRODUCTION
There are many unanswered questions in tuberculosis (TB) for
which an understanding of both clinical aspects and the adaptive
immune response is critical. Most research has concentrated on
the processes of infection and the initial, innate immune response
to Mycobacterium tuberculosis (Mtb). It has long been clear that
BCG vaccination is excellent at preventing primary forms of TB
and that the immunodeficiencies caused by HIV infection or by
increasing age give rise to these same forms of TB. On the other
hand, BCG does not prevent post-primary disease, particularly
sputum smear-positive pulmonary tuberculosis (S+PTB). Many
animal models which attempt to elucidate the nature of reacti-
vation of latent infection merely recapitulate the same pattern of
immunodeficiency found in primary disease.
Post-primary TB is characterized by an immune response
to both cross-reactive antigens, as in the tuberculin response,
and species-restricted antigens, such as those found in the RD1
sequence, namely esat-6 and cfp-10. Destructive caseation is an
essential feature of post-primary disease and much has been made
of the difference between apoptotic and necrotic cell death as the
pathogenetic mechanism (1). HIV infection has shown that CD4+
T cells are essential in this process, as lung cavities become rarer
as the CD4 count falls (2). Sette et al. observed that antigen con-
centration was important in predicting T helper responses and
that antibody responses reflected both the CD8 T cell response to
early antigens and the CD4+ T cell response to late and structural
antigens (2).
This paper will describe the data available on antibody
responses to species-restricted B cell epitopes according to clinical
parameters. It will explore whether these immunological mark-
ers can discriminate among the clinical states of TB infection and
disease. Underlying this discussion remain the problems of why
some B cell epitopes are immunodominant, how antibody diver-
sity becomes fixed, whether conformational epitopes are more
important than linear epitopes, and the relationship between T
and B cell epitopes.
THE MEASUREMENT OF EPITOPE-SPECIFIC ANTIBODY
A soluble extract from irradiated Mtb, prepared by crushing with
glass beads or ultrasonic degradation, gave a better range of anti-
gens than tuberculin (4). Mouse monoclonal antibodies (Mabs)
were created by inoculation with either Mtb or its soluble extract
and tested for specificity to Mtb (4). Competition with human sera
was tested using labeled Mabs (5), or by exploiting the difference
between mouse and human heavy chains in an ELISA (6).
LIPOPROTEIN ANTIGENS OFMYCOBACTERIUM
TUBERCULOSIS
The importance of lipoproteins to the immune response has
been demonstrated by deleting the prolipoprotein signal peptidase
(IspA) (7). S+PTB is characterized by higher levels of antibody
to mycobacterial antigens than are other forms of TB with smaller
bacterial loads. More than 80% of patients with this form of dis-
ease recognize epitopes of the 38-kDa lipoprotein antigen (Rv0934,
Antigen 5, Antigen 78, PstS1, PhoS) and epitope-specific antibody
correlates well with antibody levels to the purified antigen (8–12).
The extent of pulmonary disease has shown a positive association
with IgG antibody to the 38-kDa antigen, levels of which were
also higher in the few who died from TB (13). In S+PTB, there
is a clear association with HLA-DR15, which is also associated
with higher anti-38-kDa antibody levels (noting that the control
population in this study was from a high incidence area and the
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majority were nurses on a TB ward who were regularly exposed to
Mtb but who did not develop disease) (14). One suggestion is that
TB-associated HLA phenotypes have more focused epitope recog-
nition of TB antigens than those associated with healthy controls
(15). Another possibility is that this antigen preferentially pro-
vokes a pro-inflammatory (Th17) immune response (16). In this
context, it should be noted that the same HLA association has been
found with S+PTB in other studies in different populations (17,
18), but more importantly that this association was not found in
those with smear-negative pulmonary disease (19).
Epitope-specific (TB23 Mab) and antibody levels to the purified
19-kDa antigen (Rv3763, LpqH) contributed most to improving
the serological sensitivity after the 38-kDa antigen in a study of six
Mabs and human sera (12). Antibody levels to the purified anti-
gen were more important than its TB23 epitope in the diagnosis
of extra-pulmonary TB (20). Analysis of human T cell epitopes
showed that p61–80 peptide was important, especially in patients
with lymph node TB (21, 22).
HIV–TB co-infection has demonstrated three facts about the
role of CD4+ T cells in TB (2). Firstly, they prevent the reacti-
vation of latent TB. Secondly, they prevent disseminated disease
and their loss is associated with primary TB. Thirdly, they have
a pathogenetic role in cavitation, as cavities and significant pul-
monary infiltration become rarer as the CD4 count falls. The
majority of proteins secreted by actively dividing bacteria and rec-
ognized by polyclonal sera are fibronectin-binding proteins, such
as the antigen 85 complex, but this group includes the 38-kDa
antigen (23). Thus, these antigens are likely good serodiagnos-
tic agents for infectious TB but poor candidates for vaccines
as their recognition occurs at the same time as cavitary lung
disease.
Children with TB and those with extra-pulmonary (EP) TB
did not have antibody to the 38-kDa antigen (5). Patients with
TB meningitis, of whom 90% have no pulmonary focus, also did
not have anti-38-kDa antibody (24), nor did other patients with
primary TB (20). Studies of contacts of TB did indeed show that
antibody level to one of the 38-kDa epitopes (defined by TB72)
could be found at low but measurable levels in those with a sta-
tistically high probability of being infected (25). Perhaps early
recognition of the 38-kDa antigen indicates a subject more likely
to develop infectious S+PTB.
DORMANCY-RELATED ANTIGENS
One of the surprising findings in measuring epitope-specific anti-
body levels was the presence of antibody to the TB68 epitope of
the 16-kDa antigen (Rv2031, 14 kDa, hsp16, hspX, Acr) in nurses
on a TB ward with frequent exposure to infectious TB (26). The
bacterial load was estimated to be small in such healthy individ-
uals and, according to the Th1/Th2 hypothesis, the response in
such individuals should have been of cellular rather than humoral
immunity. Although this epitope was species-restricted, it was not
the immunodominant epitope of the purified antigen. Antibody
to the whole antigen was associated with a better prognosis, self-
healed disease, and more limited pulmonary disease (13). T cell
responses to the 16-kDa p21–40 and p111–130 peptides were also
more likely in those with BCG vaccination or EPTB compared to
S+PTB (27).
EPITOPE-SPECIFIC ANTIBODY IN LEPROSY
A series of Mabs which reacted to lipoarabinomannan (LAM) were
able to define two groups, one which reacted equally with LAM
derived from both Mtb and Mycobacterium leprae, and one series
which bound predominantly to M. leprae (28). The structural basis
for these epitopes was determined by noting the predominance of
mannose capping of LAM in Mtb (29) and using knockout mice
for embA, embB, and embC together with competitive binding to
synthetic carbohydrates (20, 30, 31). Sera from TB patients showed
no binding to the leprosy-specific epitope (unpublished data,using
the Mabs ML02 and ML34).
However, for protein antigens, antibody to the Mtb-specific epi-
topes could be detected in sera from patients with leprosy,although
no antibody to the leprosy-specific ML04 epitope (35-kDa anti-
gen) was found in TB patients (32). Two explanations exist for this
finding. Firstly, shared T cell epitopes between homologous pro-
teins in the two mycobacterial species might “help” B cells, which
had originally been stimulated in response to previous TB infec-
tion. Secondly, the antibody epitopes on homologous proteins of
M. leprae might overlap the binding site of the Mtb-specific Mabs
sufficiently to inhibit binding, there being no homolog of the M.
leprae 35-kDa antigen in Mtb. Bystander stimulation of B cells
seems less likely although the probability of exposure to leprosy
would have been less than TB (33). Conformational B cell epitopes
are flat, oblong ovals with hydrophobic amino acids at the center
surrounded by a halo of charged residues (34). Thus, antibody epi-
tope cross-reactivity is unlikely. The effect of trapping of antigen
by surface immunoglobulin influences the T cell repertoire (35)
and cryptic T cell epitopes may be revealed (36).
EPITOPE-SPECIFIC ANTIBODY DURING TB TREATMENT
Antibody levels are proportional to antigen levels and strong T
follicular helper cell responses can often initiate bystander B cell
activation hypergammaglobulinemia (3, 33). Patients with TB
characteristically have hypergammaglobulinemia. An early find-
ing in the quest for a serodiagnostic test for TB was that antibody
levels rose during treatment. This meant that evaluation of tests
required pre-treatment sera. In a detailed study of sera from 40 TB
patients during treatment (37), antibody to LAM showed a single
rise and fall in antibody titer, whereas anti-protein antibody had
an early rise within the first 2 weeks of treatment followed by a
fall and a second rise during the continuation phase of treatment.
This would be consistent with killing of different populations of
tubercle bacilli, as suggested from chemotherapy trials by Mitchi-
son (38). The rapidly dividing population is sensitive to isoniazid
and standard treatment kills 99% of bacilli in the first 2 weeks. In
this study, those with isoniazid-resistant strains of Mtb failed to
show the first rise in antibody titers (37).
In an acute inflammation, the immune response tends to be
focused on a few immunodominant antigens and a phase of
chronic inflammation is associated with epitope spreading (39).
Antigen processing by B cells is thought to be important in the
process of epitope spreading (36). In cancer immunotherapy, such
epitope spreading is associated with a good response to treatment
(40). Using vaccinia as a model of complex immune responses,
Sette et al. observed that the concentration of antigen was impor-
tant in predicting T helper responses and that antibody responses
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reflected both the CD8 T cell response to early antigens and the
CD4+ T cell response to late and structural antigens (3). The
number of epitopes recognized by TB patients increased with
treatment and was especially marked for epitopes other than the
immunodominant determinants of the 38-kDa antigen (29, 37).
Following epitope-specific antibody levels during treatment,
despite changes in antibody levels, the affinity constant for the anti-
body or antibodies to an individual epitope did not change (37).
In HIV and influenza responses, there appears to be a convergence
of epitope recognition, but “deep” sequencing has suggested that
this is accompanied by a divergence in the aminoacid sequences
forming the antibody binding site (41). This would suggest that
affinity should continue to improve and the absence of such a
change during TB treatment is therefore surprising and requires
further investigation.
Can the changes in epitope-specific antibody levels predict cure
or relapse? Preliminary evidence suggests that antibody to the dor-
mancy antigen α-crystallin (TB68 epitope of the 16-kDa antigen)
might be helpful in predicting relapse during treatment, but as
antibody levels persisted beyond successful treatment, a biomarker
of cure still eludes us (37).
CONCLUSION
Antigen recognition varies across the TB spectrum. Antigen con-
centration is likely responsible for the immunodominance of
epitopes of secreted proteins in S+PTB. There may be a role
for measuring antibody/T cell responses to dormancy antigens
and some lipoproteins as predictors of disease and biomarkers of
protection and response to treatment.
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